INmune Bio, Inc. (INMB) is a Healthcare stock trading at $2.30 (as of 2026-08-21), with a market capitalization of $63.83M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
INmune Bio, Inc. is a clinical-stage immunotherapy company developing treatments designed to reprogram a patient’s innate immune system. Its product pipeline targets hematologic malignancies, solid tumors, chronic inflammation, and Alzheimer’s disease, including programs such as INKmune, INB03, and XPro1595.
INmune Bio develops and commercializes innate-immune reprogramming immunotherapy drugs for hematologic malignancies, solid tumors, and chronic inflammation, using programs including INKmune, INB03, and XPro1595.
Because the company is focused on developing and commercializing clinical immunotherapy programs, its profit model depends on whether progress in these programs can translate into commercially available therapies.
Business quality (Weak): Limited segment detail is provided, and several financial fields are not available, but the latest quarter includes specific program activity and an operating loss.
| Price | $2.30 |
| Market Cap | $63.83M |
| Price / Book | 3.13 |
| Price / Sales | 389.23 |
| FCF Yield | -32.2% |
| Revenue (TTM) | $50000.00 |
| Net Margin | -91866.0% |
| Revenue Growth (YoY) | 257.1% |
| EPS Growth (YoY) | -11.8% |
| Altman Z-Score | -8.93 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | VANGUARD GROUP INC ($1.49M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | David J. Moss |
| Employees | 13 |
| Country | US |
| IPO Date | 2019-02-04 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.